Travirtide (CGP)

Travirtide (CGP) is a clinical-grade peptide designed to significantly boost viral gene transfer efficiency, particularly in T cells and other mammalian cells. Designed for research in cancer, infection, and gene therapy, Travirtide supports applications such as CAR-T and TCR-T cell engineering by facilitating retroviral vector entry. Its rapid and robust performance makes it a valuable tool in reducing manufacturing complexity and cost in advanced cellular therapies.

Travirtide (CGP) - Specifications

• Amount: 1.0 mg net (AAA)
• Purity: Clinical Grade: >95% (HPLC/MS)
• Counterion: chloride
• Delivery Format: Freeze-dried in Crystal Zenith vial
• MW (average): 1440.75
• Application(s): T-cell immunity, Transduction
• Condition(s)/Topic(s): Cancer, Infection, Gene therapy, non-Hodgkin lymphoma
• Standard Delivery Time: 2-5 days

Are you interested in other peptides or conjugation to a protein, nucleic acid or lipid? Choose your sequence, amount and purity with our Custom Peptide Synthesis services.

Understanding Viral Transduction Enhancers

Gene transfer using viral vectors is a fundamental tool in modern biomedical research. It is essential for projects involving disease model validation and the development of novel therapies for cancer and infectious diseases. One prominent application is the use of genetically modified T cells, such as CAR-T and TCR-T cells, in immunotherapy.Despite their promise, these therapies remain expensive, partly due to inefficient gene transfer. Retroviral transduction, a key step in these protocols, is often limited by low efficiency. Various enhancers, including surfactants, fibril-forming peptides, and specialized coatings, have been explored, but many introduce complexity and time-consuming handling steps.

Benefits of JPT's Transduction Enhancer: Travirtide (CGP)

Travirtide (CGP) addresses these challenges by offering a peptide-based solution for enhancing viral gene transfer. Benefits include:

• Strong transduction enhancement (see poster)
• Higher transduction efficacy than competitors (see poster)
• Low cytotoxicity
• Good aqueous solubility
• No preservatives added
• High potency in facilitating retroviral transduction
• Broad compatibility with viral vectors
• Simple, rapid protocol with minimal handling
• Potential to reduce costs in CAR-T production workflows

Make sure to take a look at our conference poster about Travirtide™!

Travirtide promotes efficient viral entry into mammalian cells and supports a wide range of transduction experiments, helping researchers streamline their protocols in gene therapy and cell-based immunotherapy research.